Back to Blog

Supplementary Protection Certificate: 5 Essential Rules

Supplementary protection certificate extending a pharmaceutical patent term

A blockbuster drug can spend a decade in clinical trials and regulatory review before it ever reaches a pharmacy shelf. By the time it is approved, much of its 20-year patent term has already burned away while the product earned nothing. The supplementary protection certificate is Europe’s answer to that problem: a special right that extends patent protection for approved medicines and plant-protection products by up to five years, compensating for the years lost to regulatory delay. For anyone commercialising a pharmaceutical or agrochemical in Europe, it is often worth more than the underlying patent. This guide explains what it is, how long it lasts, the deadline you cannot miss, and how it differs from the US equivalent.

What a Supplementary Protection Certificate Does

Supplementary protection certificate pharmaceutical patent timeline
Photo: NanningTianchiShanPharmacy by Fรฉlix An (CC BY 4.0)

A supplementary protection certificate is a sui generis intellectual property right that comes into force the moment a basic patent expires, extending the exclusivity on a specific approved product. It exists because of a timing mismatch unique to regulated industries: you must patent an invention early, long before you can sell it, yet you cannot market a medicine until regulators grant a marketing authorisation. The years spent in trials and review are years of patent term with no return.

In the European Union, the certificate is governed by Regulation (EC) No 469/2009 for medicinal products, with a parallel regulation covering plant-protection products. The certificate does not revive the whole patent โ€” it protects only the product covered by the marketing authorisation, within the scope of the basic patent. That narrowing is the point: it rewards the specific approved medicine, not the broader chemistry around it.

Rule 1: How Long an SPC Lasts

The duration is set by a formula, not a flat term. You take the time that elapsed between the filing date of the basic patent and the date of the first marketing authorisation in the European Economic Area, then subtract five years. The result is how long the certificate runs after the patent expires โ€” capped at a maximum of five years.

There is a second ceiling that matters just as much: the total protection from the patent and the certificate combined cannot exceed fifteen years from the first marketing authorisation. In plain terms, Europe guarantees an approved product roughly fifteen years of exclusivity counted from approval, no matter how long the regulatory road was.

A worked example makes it concrete. If eleven years passed between patent filing and first approval, eleven minus five is six, but the five-year cap applies, so the certificate runs the full five years. By contrast, a product approved only eight years after filing yields eight minus five, or three years of extra term. The faster the approval, the shorter the extension, because less patent life was lost in the first place.

That formula rewards candour about your real timeline. The relevant authorisation is the first one anywhere in the European Economic Area, not the first in the country where you are filing, so a group that launches early in one member state starts the clock for all of them. Getting the dates right is not a formality โ€” a single wrong entry can shorten a certificate worth a fortune.

Rule 2: The Six-Month Deadline to Apply

Supplementary protection certificate six-month filing deadline calendar
Photo: Japan-Canada Summit Meeting (1) by Government of Japan (CC BY 4.0)

The deadline is where valuable certificates are lost, and it is unforgiving. Under Article 7 of the Regulation, the application must be filed within six months of the marketing authorisation being granted. There is one variation: where the authorisation is granted before the basic patent, the clock instead runs six months from the date the patent is granted.

Miss that window and the right is gone โ€” there is no routine extension or late-filing cure, so the diary date has to be managed the day an authorisation issues. Because an SPC is national, that means tracking the deadline in every country where you want protection, which is a docketing discipline rather than a one-off task. The same deadline rigour applies across patent prosecution generally; our overview of patent term adjustment and extension covers the adjacent US mechanisms.

Rule 3: The Six-Month Paediatric Extension

A certificate can be extended once, by a further six months, for medicines that have been studied in children. The condition is that the company completes an agreed Paediatric Investigation Plan and reflects the results in the product information, whether or not the studies showed a paediatric benefit.

The reward is significant: six extra months on a top-selling medicine can be worth hundreds of millions in revenue, which is precisely why the incentive exists โ€” to pull companies into running paediatric trials they might otherwise skip. Stacked on top of the five-year maximum, the paediatric extension lifts the overall ceiling to fifteen and a half years of protection from first approval.

Rule 4: It Is National, Not Unitary (Yet)

Unlike the European patent with unitary effect, there is no single pan-European certificate. Each one is applied for and granted by a national patent office, and it stands or falls on its own in each country. A proposal for a unitary supplementary protection certificate has been under discussion in Brussels since 2023, but as of late 2026 it remains stalled in the Council and is not yet law.

Brexit added a wrinkle. Since 1 January 2021 the United Kingdom has run its own certificate regime, built on the retained EU rules and administered by the UK Intellectual Property Office. The substantive requirements remain close to the EU model, but it is now a separate filing and a separate right, so UK protection has to be pursued deliberately rather than assumed to follow from an EU grant.

Rule 5: SPC vs US Patent Term Extension

The United States solves the same regulatory-delay problem with a different tool: Patent Term Extension under the Hatch-Waxman Act (35 U.S.C. ยง 156). The headline numbers look similar โ€” up to five years of extension, with a cap of fourteen years of protection from approval โ€” but the mechanics differ. A US extension attaches to the patent itself and only one patent can be extended per approved product, whereas in Europe a certificate is a separate right and can, in principle, be sought on more than one basic patent covering the product.

  • Europe โ€” a standalone certificate; up to 5 years; 15-year cap from first approval; six-month filing deadline; national grant.
  • United States โ€” an extension of the patent term under ยง 156; up to 5 years; 14-year cap from approval; one patent per product.
  • Shared logic โ€” both restore time lost to clinical trials and regulatory review, not time lost to the applicant’s own delay.

The strategic takeaway for a global product is that the two systems must be planned together, not treated as copies. The timing of your first approvals in each region drives the value of the extension you can capture โ€” a calculation that feeds directly into the kind of lifecycle planning we discuss in our pharma patent cliff and semaglutide patent expiration analyses.

How PerspireIP Can Help

A supplementary protection certificate is often the single most valuable asset in a pharmaceutical portfolio, and its value turns on deadlines measured in months. PerspireIP helps innovators identify which patents can anchor a certificate, docket the six-month filing windows across Europe and the UK, and coordinate European protection with US patent term extension. Talk to our team about protecting the full commercial life of your product.

Frequently Asked Questions

What is a supplementary protection certificate?

It is a European intellectual property right that extends the protection of a patented medicine or plant-protection product for up to five years after the basic patent expires, compensating for the time lost to clinical trials and regulatory approval.

How long does an SPC last?

Its term equals the time between the patent’s filing date and the first EEA marketing authorisation, minus five years, capped at a maximum of five years. Total patent-plus-certificate protection cannot exceed fifteen years from the first approval.

What is the deadline to apply for an SPC?

Under Article 7 of Regulation 469/2009, you must file within six months of the marketing authorisation being granted, or within six months of the patent grant if the authorisation came first. Missing the deadline forfeits the right.

What is the paediatric extension?

A certificate can be extended once by six months if the company completes an agreed Paediatric Investigation Plan for the medicine. This raises the overall protection ceiling to fifteen and a half years from first approval.

Is there a single SPC covering all of Europe?

Not yet. Each certificate is granted nationally by individual patent offices. A unitary SPC has been proposed in the EU since 2023 but, as of late 2026, remains stalled in the Council and is not in force.

How does an SPC differ from US patent term extension?

Both restore term lost to regulatory delay and both cap at five years of extension. But a European certificate is a separate right granted nationally, while a US extension under 35 U.S.C. ยง 156 extends the patent itself and is limited to one patent per approved product.